PRVB: Hold Nose, Buy More
Provention Bio (PRVB) announced the FDA needs more PK/PD data. Here’s why I’m buying more on this pullback…
Provention Bio (PRVB) announced the FDA needs more PK/PD data. Here’s why I’m buying more on this pullback…
To invest in biotech is to invest in the future. And with this unique, under-the-radar company, we can do so with dramatically reduced risk
Ignore the short-term price action in Atomera (ATOM) and focus on the steadily improving business fundamentals…
The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)
The latest data out of Immunome underscores the superiority of its approach and adds urgency to the opportunity. Here’s why…
Provention Bio (PRVB) announced an offering after the bell yesterday, on a day teh stock hit a 52-week high. Here’s what I plan to do…
With micro-caps surging and the Covid-19 pandemic underscoring the vital need for new drugs and therapies, this micro-cap is perfectly positioned to capitalize on the momentum in both areas of the market.
After rallying 700%+ since our entry, here’s what I expect to propel shares of Atomera Inc. (ATOM) even higher from here…
Atomera Inc. (ATOM) announced its first JDA partner. Here’s why the agreement immediately justifies a revaluation of share to ~$50+